PRESS RELEASE

CARMAT is participating in the 28th EACTS Annual Meeting in Milan (Italy)

Presentation of the portable system project for patient home discharge

Paris, October 9, 2014

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage heart failure, today announces its participation in the 28th EACTS (European Association for Cardio-Thoracic Surgery) Annual Meeting held in Milan (Italy) from October 11 to 15, 2014.

During the exhibition that will run in parallel to the scientific sessions from October 12 to 14, the Company will notably present, on its booth (#75-76), its portable system project[1], the configuration that aims to allow patients who will have been implanted with its self-regulated bioprosthetic heart to leave hospital and return home under good conditions.

"*Being discharged from hospital and returning to their lives is very important for patients. The availability of our portable system will therefore be a major milestone for the Company*", comments Marcello Conviti, CARMAT's CEO. He adds: "*When a patient is discharged from hospital, not only does this have obvious economic benefits for healthcare systems, but – more importantly – the renewed quality of life that these portable systems could provide will play a key role in the adoption of our bioprosthesis by doctors and their patients.*"

●●●

About CARMAT: the world's most advanced total artificial heart project

A credible response to end-stage heart failure: CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.

The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

Imitating the natural heart: given its size, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming the necessary clinical trials are successful, potentially benefit the lives of thousands of patients a year with no risk of rejection and with a good quality of life.

---

1 *For further information, please refer to the 6th Shareholder Newsletter, which is available on the Company's website www.carmatsas.com, in the Investors / Documentation / Shareholder Newsletter section.*

A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.

Strongly committed, prestigious founders and shareholders: Airbus Group, Professor Alain Carpentier, the Centre Chirurgical Marie Lannelongue, Truffle Capital, a leading European venture capital firm, and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

For more information: *www.carmatsa.com*

●●●

●●●

CARMAT
Marcello Conviti
CEO

Patrick Coulombier
COO

Valérie Leroy
Director of Marketing
& Investor Relations

Tel.: +33 (0)1 39 45 64 50
contact@carmatsas.com

Alize RP
Press Relations

Caroline Carmagnol

Tel.: +33 (0)1 70 22 53 90
caroline@alizerp.com

NewCap
Financial Communication
and Investor Relations

Dusan Oresansky
Emmanuel Huynh

Tel.: +33 (0)1 44 71 94 94
carmat@newcap.fr

ALCAR
LISTED
ALTERNEXT

Name: **CARMAT**
ISIN code: **FR0010907956**
Ticker: **ALCAR**